B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1

B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 — Trials · CancerIndex

Clinical trials

Registered studies

39 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 18
Recruiting: 8
Ph III recruiting: 0
Growth YoY: —
Industry share: 6%
Top sponsor: M.D. Anderson Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–8 of 8 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07224100	Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma	recruiting	Phase 2	33	University of WashingtonOTHER	1	Aug 13, 2026	clinicaltrials
NCT02727803	Personalized NK Cell Therapy in CBT	recruiting	Phase 2	100	M.D. Anderson Cancer CenterOTHER	1	Jul 30, 2026	clinicaltrials